Drug Profile
Research programme: pancratistatin derivatives - Aptose Biosciences/Brock University
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Brock University; Lorus Therapeutics
- Developer Aptose Biosciences; Brock University
- Class Alkaloids; Isoquinolines; Small molecules
- Mechanism of Action Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Canada (PO)
- 02 Sep 2014 Lorus Therapeutics is now called Aptose Biosciences
- 18 Dec 2012 Early research in Cancer in Canada (PO)